Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Primary Axillary Hyperhidrosis Clinical Trial

Official title:

An Open-label, Uncontrolled, Multicenter Study to Evaluate the Safety, Local Tolerability, Systemic Exposure, and Efficacy of 1% Glycopyrronium Bromide (GPB) Cream in Adolescents With Severe Primary Axillary Hyperhidrosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05863104
• Other study ID #: GPBK-08/2018
• Status: Completed
• Phase: Phase 2
• Start date: March 7, 2023
• Est. completion date: March 6, 2024

Study information

• Verified date: April 2024
• Source: Dr. August Wolff GmbH & Co. KG Arzneimittel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 6, 2024
• Est. primary completion date: March 6, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

• Medical diagnosis of severe primary axillary hyperhidrosis with a PRHS score of =5 with symptoms for at least 3 months before Screening
• At least 50 mg of sweat production in each axilla measured gravimetrically over a period of 5 minutes at room temperature along with a humidity consistent with the normal climate in that area (patients have to acclimatize to that room for at least 30 minutes before the measurement)
• Adolescents of both sexes aged 12 to 17 years (until study completion) with a body mass index percentile =10 and =90 (according to Kromeyer-Hauschild et al 2001)
• Local tolerability assessment (skin reaction) score = 0

Exclusion Criteria:

• Secondary hyperhidrosis, ie, hyperhidrosis that is secondary to other underlying diseases such as (but not limited to) hyperthyroidism, lymphoma, and malaria
• Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage, ultrasonic surgery, microwave treatment (miraDry), or laser treatment
• Botulinum toxin treatment for the treatment of axillary hyperhidrosis in the previous 4 months
• Hypersensitivity to glycopyrrolate, or to any of the excipients of the investigational medicinal product (IMP)

Related Conditions & MeSH terms

• Hyperhidrosis
• Primary Axillary Hyperhidrosis

Intervention

Drug:
• Glycopyrronium Bromide (GPB) Cream
Application of cream to each axilla

Locations

Country	Name	City	State
Germany	Dr. Michael Sebastian	Mahlow

Sponsors (1)

Lead Sponsor	Collaborator
Dr. August Wolff GmbH & Co. KG Arzneimittel

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with Adverse Drug Reaction during treatment		Baseline to Day 57
Primary	Number of patients with a local tolerability assessment (skin reaction score) >0 during treatment		Baseline to Day 57
Primary	?bsolute change in GP plasma concentration from Baseline to Day 15		Baseline to Day 15
Secondary	Absolute change in logarithmic values of total sweat production assessed by GM from Baseline to Day 29		Baseline to Day 29
Secondary	Absolute change in logarithmic values of total sweat production assessed by GM from Baseline to Day 57		Baseline to Day 57
Secondary	Absolute change in logarithmic values of total sweat production assessed by GM from Day 29 to Day 57		Day 29 to Day 57
Secondary	Relative change in total sweat production assessed by GM from Baseline to Day 29 and Day 57		Baseline to Day 29 and Day 57
Secondary	Relative change in total sweat production assessed by GM from Day 29 to Day 57		Day 29 to Day 57
Secondary	Proportion of responders assessed by GM at Day 29 and Day 57		Day 29 and Day 57
Secondary	Absolute change in patient-rated hyperhidrosis severity (PRHS) score from Baseline to Day 29 and Day 57	The patient-rated hyperhidrosis severity (PRHS) score will be assessed by asking the following question: "How did you perceive your underarm sweating in the past 24 hours? Please rate it on a scale from 0 (no sweating at all) to 10 (worst sweating that you ever had)"	Baseline to Day 29 and Day 57
Secondary	Absolute change in patient-rated hyperhidrosis severity (PRHS) score from Day 29 to Day 57	The patient-rated hyperhidrosis severity (PRHS) score will be assessed by asking the following question: "How did you perceive your underarm sweating in the past 24 hours? Please rate it on a scale from 0 (no sweating at all) to 10 (worst sweating that you ever had)"	Day 29 to Day 57
Secondary	Absolute change in the Children's dermatology life quality index (CDLQI) score from Baseline to Day 29 and Day 57	The Children's dermatology life quality index (CDLQI) is a simple 10-question questionnaire that assesses the burden of hyperhidrosis. It is validated for children aged 5-16 years. The answers to the questions are generally scored on a 4-point scale: 'very much' = 3, 'quite a lot' = 2, 'only a little' = 1, 'not at all' or question unanswered = 0.; The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more impairment of the child's life is experienced.	Baseline to Day 29 and Day 57
Secondary	Absolute change in the Children's dermatology life quality index (CDLQI) score from Day 29 to Day 57	The Children's dermatology life quality index (CDLQI) is a simple 10-question questionnaire that assesses the burden of hyperhidrosis. It is validated for children aged 5-16 years. The answers to the questions are generally scored on a 4-point scale: 'very much' = 3, 'quite a lot' = 2, 'only a little' = 1, 'not at all' or question unanswered = 0.; The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more impairment of the child's life is experienced.	Day 29 to Day 57
Secondary	Absolute change in GP plasma concentration from Baseline to Day 8		Baseline to Day 8
Secondary	Absolute change in GP plasma concentration from Day 8 to Day 15		Day 8 to Day 15
Secondary	Frequency, severity, and relation of ADRs, SAEs, TEAEs, SUSARs, and discontinuations due to TEAEs		Screening to 14 Days after End of Treatment
Secondary	Local tolerability based on the skin reaction score	Local tolerability at the application sites will be assessed and evaluated by the investigator using a skin reaction score: 'No evidence of irritation' = 0, 'Minimal erythema, barely perceptible' = 1, 'Definite erythema, readily visible; minimal edema or minimal popular response' = 2, 'Erythema and papules' = 3, 'Definite edema' = 4, 'Erythema, edema, and papules' = 5, 'Vesicular eruption' = 6, 'Strong reaction spreading beyond test site' = 7, 'Folliculitis' = 8.	Day 1, Day 29, Day 57/End of Treatment and 14 Days after Day 57/End of Treatment
Secondary	Neurological assessment of anticholinergic effects by a 4-point scale	The occurrence of possible anticholinergic effects including dry mouth, dry eyes, blurred vision, red eyes, constipation, micturition disorder, drowsiness, and concentration difficulties is rated on a 4-point scale: 'severe intensity' = 3, 'moderate intensity' = 2, 'mild intensity' = 1, 'no evidence' = 0.	7 to 4 Days before Baseline, Day 15, Day 29, Day 43, Day 57/End of Treatment